AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02259231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Description: Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
Study NCT02259231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg)
Description: Sterile solution containing nivolumab to be delivered intravenously at 240 mg
Study NCT02259231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (10 mg/capsule)
Description: Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Study NCT02259231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Capsules (50 mg/capsule)
Description: Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
Study NCT01515072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC (Remote Ischemic Preconditioning)
Description: Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
Study NCT03135093 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study NCT01508676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pennsaid
Study NCT01508676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.3% DMSO solution)
Study NCT03303430 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Diffusion weighted imaging 24 hours after revascularisation
Study NCT00567931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-d-tryptophan
Description: Given orally
Study NCT00567931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00567931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03652454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Description: Propel device (ABD) using for regional acceleratory phenomenon
Study NCT03652454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional fixed appliance treatment
Description: conventional fixed appliance treatment
Study NCT03652454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional fixed appliance treatment
Description: conventional fixed appliance treatment
Study NCT00929630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphincteric Seton positioning
Description: A cutting seton is applied into the fistula tract
Study NCT00929630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glue (Tissucol) treatment
Description: After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
Study NCT00929630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistula closing with biological glue
Description: After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
Study NCT00929630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seton positioning into the fistula tract
Description: Under spinal anesthesia a Seton is positioned into the fistula tract.
Study NCT02228499 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
Study NCT01677845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions.
Study NCT04476264 — intervention group
Intervention type: PROCEDURE
Intervention: Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection
Description: The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
Study NCT03728244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO ointment
Description: The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
Study NCT03728244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid gel
Description: Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 50 mg
Description: Oral tablet(s) containing GLPG2222
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 100 mg
Description: Oral tablet(s) containing GLPG2222
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet(s) containing placebo
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 200 mg
Description: Oral tablet(s) containing GLPG2222
Study NCT03119649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2222 400 mg
Description: Oral tablet(s) containing GLPG2222
Study NCT04661696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (albumin-bound)
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
Study NCT00663130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
Study NCT00663130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
Study NCT02739464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + SOC PT/OT
Study NCT02739464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC PT/OT
Study NCT04375878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS1819
Description: MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
Study NCT01267955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01267955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT02642042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02642042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03118557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates pelvic floor strengthening
Description: Pilates pelvic floor strengthening.
Study NCT00706277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
Study NCT00706277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2mg
Study NCT04375878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Porcine PERT
Description: Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
Study NCT00706277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil 0,25mcg/kg/hour
Study NCT00706277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl 100mcg
Study NCT00706277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane/Nitrous Oxide
Description: maintenance of anesthesia with sevoflurane and nitrous oxide
Study NCT05260697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexual counselling with plissit model
Description: sexual counselling
Study NCT00152451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seletracetam (ucb 44212)
Description: * Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration
Study NCT03904329 — intervention group
Intervention type: DRUG
Intervention: Oral Anticoagulant
Description: Oral tablets of anti coagulations either warfare or NOACs
Study NCT00463684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine
Description: Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
Study NCT00463684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated measles vaccine
Description: Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
Study NCT04501003 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)
Description: With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
Study NCT00115063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group sessions
Description: group sessions lead by a trained primary care clinic employee
Study NCT00115063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine, orlistat, diethylpropion
Description: dosage modified according to package insert instructions at discretion of primary care physicians
Study NCT00115063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet, Health One
Description: liquid diet for 8-12 weeks to induce weight loss
Study NCT00115063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Medical Combination Therapy for Obesity
Description: Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox.
Study NCT00115063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Access to the Mayo Clinic weight management website and usual care from the primary care physician
Study NCT02477787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic, donor-derived NK cells
Description: Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions.
Study NCT02137330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Obalon® Gastric Balloon
Study NCT00966485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mg ASA dosing
Study NCT00966485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg ASA dosing
Study NCT01717339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleep Study
Study NCT03733444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.
Study NCT03733444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo, film-coated tablets for oral use.
Study NCT05462327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Fresh Gas Flow in Prone Position
Description: In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
Study NCT05462327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Fresh Gas Flow in Prone Position
Description: In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
Study NCT01019421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054
Description: Add-on treatment to donepezil
Study NCT01019421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Add-on treatment to donepezil
Study NCT01015625 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
Study NCT01015625 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery on Demand
Description: if necessary local therapy on demand
Study NCT01902394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grains
Description: Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
Study NCT01902394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grains
Description: Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
Study NCT02962752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackadder Juice
Study NCT02962752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00688571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Transcatheter Pulmonary Valve
Description: Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
Study NCT00838539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT00838539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT02642042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2).
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2).
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups).
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups).
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8.
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8.
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenograstim
Description: Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l.
Study NCT01180322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l.
Study NCT01169558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
Study NCT01169558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based Chemotherapy
Description: Fluoropyrimidine-based chemotherapy administered according to standard of care.
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300 mg capsule administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg capsule administered orally with food once daily
Study NCT01705574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100 mg tablet administered orally with food once daily